Just-Evotec Biologics
Sandoz announces collaboration agreement with Shanghai Henlius Biotech
The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company
Sandoz partners with Samsung Bioepis to develop up to five biosimilars
The agreement will expand the pipeline and builds on an existing partnership
Sandoz appoints Armin Metzger as President of new global unit
Metzger was most recently Executive VP, Chief Technical Operations Officer at Ferring Pharmaceuticals
Sandoz launches first and only multiple sclerosis biosimilar in US
The treatment is FDA-approved to treat MS and Crohn’s disease
Sandoz to acquire Just-Evotec Biologics to strengthen biosimilar development and manufacturing capabilities
Acquisition will add in-house continuous manufacturing expertise and expand Sandoz’s biosimilar production capacity
EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy
An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019
FDA grants interchangeable designation to Celltrion’s Humira biosimilar Yuflyma
The drug is approved for inflammatory conditions such as Crohn's disease and plaque psoriasis
EC approves Biocon’s Stelara biosimilar Yesintek for inflammatory diseases
The drug has been approved to treat plaque psoriasis, psoriatic arthritis and Crohn’s disease
EC approves Celltrion’s Stelara biosimilar SteQeyma for inflammatory diseases
The drug has been authorised for use in gastroenterology, dermatology and rheumatology indications
Sandoz receives FDA approval for first denosumab biosimilars Wyost and Jubbonti
The biosimilars have been authorised for all indications covered by Amgen's reference medicines
Sandoz separates from Novartis as an independent spin-off company
The split allows Sandoz to strengthen its position in generics and biosimilars
Sandoz biosimilar receives EC approval to treat MS
Tyruko is the first and only biosimilar treatment for relapsing-remitting MS in Europe